KA/EN
Register
Medicines reference
Search
Search
Active substance

Mirtazapine

Favourites

Tetracyclic antidepressant, appetite stimulant. Registered in Georgia: 4 human medicines. Forms: tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Mirtazapine
Dose Species Indication Route Frequency Source
2 mg per animal
at most 2 mg
 Cat Maintenance On the skin once daily
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Mirataz 20 mg/g transdermal ointment for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in breeding, pregnant or lactating cats.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in breeding, pregnant or lactating cats.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals less than 7.5 months of age or less than 2 kg body weight.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning
    In the case of hepatic disease, elevated hepatic enzyme levels may be observed.
    Sources: VMD SPC · VMD
  • Warning
    Kidney disease may cause reduced clearance of mirtazapine, which may result in higher drug exposure.
    Sources: VMD SPC · VMD

Known Drug Interactions

Latin name
Mirtazapine
Georgian name
მირტაზაპინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
4 of 4 forms
Products
Adep, Mirtazapine Normon, Mirtel, Mirtoza
Human medicines in Georgia
Adep, Mirtel, Mirtoza
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration4

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Adep 30 mg, Tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause
5.9/10
Weak evidence support
vetman assessment

Adep

30 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-041752 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine has current evidence as a short-term second-line appetite stimulant in selected dogs, but this whole-only 30 mg human tablet is poorly scaled to many patients. Diagnose and treat the cause of hyporexia, use a validated patient-specific dose, review serotonergic combinations and escalate to assisted nutrition when intake remains inadequate.

Regulatory and scientific credibility5.5/10

The exact human 30 mg tablet is currently registered in Georgia, but no exact EU/EEA, GB or US registration and no veterinary authorisation were found in the checked registers. Oral species evidence supports mirtazapine as an ingredient, not the dose accuracy or veterinary suitability of this exact whole-only presentation.

Clinical efficacy6.5/10

A 2025 study combined 107 retrospective clinical cases with a 25-dog placebo-controlled crossover trial: mirtazapine improved voluntary food acceptance on day 1 and was associated with less weight loss, but the prospective advantage was not maintained on day 2. This supports a useful short-term second-line role, not replacement of diagnosis, anti-nausea treatment or assisted enteral nutrition.

Safety and tolerability6.0/10

The current placebo-controlled study reported no short-term adverse effects, but canine safety numbers remain modest. Sedation or excitation, gastrointestinal signs, cardiovascular change and serotonin toxicity are plausible; human labelling and class pharmacology require review of serotonergic drugs, monoamine-oxidase inhibitors, organ disease and repeated exposure.

Clinical practicality5.5/10

A 30 mg whole-only tablet can match some very large dogs but is poorly scaled to many canine doses. Crushing may permit pharmacy compounding, but informal powder division or guessed fragments do not establish content uniformity; use a validated patient-specific preparation rather than improvised fractions.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • The 30 mg tablet is whole-only in the catalogue and is too large for many canine regimens. Do not assume that crushing makes home division accurate; use a pharmacy-validated patient-specific preparation when the prescribed dose is not a whole tablet.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA mirtazapine alternatives2023
  5. Dog appetite mirtazapine2025
  6. Dog mirtazapine PK2012
  7. AAHA nutrition guideline2021
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause
5.8/10
Weak evidence support
vetman assessment

Adep

30 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-041752 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine can improve appetite and weight and reduce vomiting in selected cats, especially those with stable CKD, but this whole-only 30 mg tablet is an unsafe practical match to the approximately 1.88-2 mg studied dose. Prefer an authorised feline formulation or an accurately prepared low-dose product and adjust monitoring for renal or hepatic disease.

Regulatory and scientific credibility5.5/10

The exact human 30 mg tablet is currently registered in Georgia, but no exact EU/EEA, GB or US registration and no veterinary authorisation were found in the checked registers. Oral species evidence supports mirtazapine as an ingredient, not the dose accuracy or veterinary suitability of this exact whole-only presentation.

Clinical efficacy7.5/10

A masked placebo-controlled crossover trial in 11 cats with stable CKD found improved appetite and activity, reduced vomiting and median weight gain of 0.18 kg over three weeks; healthy-cat pharmacodynamic work also showed increased intake. Samples are small and do not establish equal benefit in every cause of feline hyporexia, but oral efficacy is clinically credible.

Safety and tolerability6.5/10

Feline oral studies define common behavioural and gastrointestinal effects and show slower clearance in renal and especially hepatic disease. An 84-case toxicosis series found vocalisation, agitation, vomiting, ataxia, tremor, tachypnoea and tachycardia, commonly after 15 mg accidental ingestion; an accurately measured low dose is therefore central to safety.

Clinical practicality2.0/10

The studied oral feline dose is about 1.88-2 mg, roughly one sixteenth of this 30 mg whole-only tablet. That dose cannot be delivered accurately by ordinary splitting, and accidental administration of 15-30 mg is a documented toxicosis pattern. A licensed feline product or validated low-dose compounded preparation is far more practical.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • This whole-only 30 mg tablet cannot accurately deliver the approximately 1.88-2 mg oral dose studied in cats. Do not estimate one-sixteenth fragments or dispense loose hand-divided powder; use an authorised feline product or a pharmacy-validated low-dose preparation.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA feline mirtazapine2026
  5. Cat CKD mirtazapine RCT2013
  6. Cat mirtazapine PK PD2011
  7. Cat CKD mirtazapine PK2011
  8. Cat mirtazapine toxicosis2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Mirtazapine30 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Welfare United
Registration
Georgia Yes, human
In force until 01 Aug 2029
Human (Ministry of Health, RAMA)
In the register: ადეპი 30 მგ, აბი
№ რ-041752
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Mirtazapine Normon 30 mg, Tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause
6.1/10
Situational / acceptable
vetman assessment

Mirtazapine Normon

30 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043965 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine has current evidence as a short-term second-line appetite stimulant in selected dogs, but this whole-only 30 mg human tablet is poorly scaled to many patients. Diagnose and treat the cause of hyporexia, use a validated patient-specific dose, review serotonergic combinations and escalate to assisted nutrition when intake remains inadequate.

Regulatory and scientific credibility6.0/10

The exact human 30 mg tablet has sourced current Georgian and EU/EEA registration and a transparent immediate-release identity, but no veterinary authorisation. Oral mirtazapine has current species evidence and professional-guideline support; those data do not validate this whole-only 30 mg presentation as a directly deliverable veterinary dose.

Clinical efficacy6.5/10

A 2025 study combined 107 retrospective clinical cases with a 25-dog placebo-controlled crossover trial: mirtazapine improved voluntary food acceptance on day 1 and was associated with less weight loss, but the prospective advantage was not maintained on day 2. This supports a useful short-term second-line role, not replacement of diagnosis, anti-nausea treatment or assisted enteral nutrition.

Safety and tolerability6.0/10

The current placebo-controlled study reported no short-term adverse effects, but canine safety numbers remain modest. Sedation or excitation, gastrointestinal signs, cardiovascular change and serotonin toxicity are plausible; human labelling and class pharmacology require review of serotonergic drugs, monoamine-oxidase inhibitors, organ disease and repeated exposure.

Clinical practicality5.5/10

A 30 mg whole-only tablet can match some very large dogs but is poorly scaled to many canine doses. Crushing may permit pharmacy compounding, but informal powder division or guessed fragments do not establish content uniformity; use a validated patient-specific preparation rather than improvised fractions.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • The 30 mg tablet is whole-only in the catalogue and is too large for many canine regimens. Do not assume that crushing makes home division accurate; use a pharmacy-validated patient-specific preparation when the prescribed dose is not a whole tablet.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA mirtazapine alternatives2023
  5. Dog appetite mirtazapine2025
  6. Dog mirtazapine PK2012
  7. AAHA nutrition guideline2021
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause
5.9/10
Weak evidence support
vetman assessment

Mirtazapine Normon

30 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043965 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine can improve appetite and weight and reduce vomiting in selected cats, especially those with stable CKD, but this whole-only 30 mg tablet is an unsafe practical match to the approximately 1.88-2 mg studied dose. Prefer an authorised feline formulation or an accurately prepared low-dose product and adjust monitoring for renal or hepatic disease.

Regulatory and scientific credibility6.0/10

The exact human 30 mg tablet has sourced current Georgian and EU/EEA registration and a transparent immediate-release identity, but no veterinary authorisation. Oral mirtazapine has current species evidence and professional-guideline support; those data do not validate this whole-only 30 mg presentation as a directly deliverable veterinary dose.

Clinical efficacy7.5/10

A masked placebo-controlled crossover trial in 11 cats with stable CKD found improved appetite and activity, reduced vomiting and median weight gain of 0.18 kg over three weeks; healthy-cat pharmacodynamic work also showed increased intake. Samples are small and do not establish equal benefit in every cause of feline hyporexia, but oral efficacy is clinically credible.

Safety and tolerability6.5/10

Feline oral studies define common behavioural and gastrointestinal effects and show slower clearance in renal and especially hepatic disease. An 84-case toxicosis series found vocalisation, agitation, vomiting, ataxia, tremor, tachypnoea and tachycardia, commonly after 15 mg accidental ingestion; an accurately measured low dose is therefore central to safety.

Clinical practicality2.0/10

The studied oral feline dose is about 1.88-2 mg, roughly one sixteenth of this 30 mg whole-only tablet. That dose cannot be delivered accurately by ordinary splitting, and accidental administration of 15-30 mg is a documented toxicosis pattern. A licensed feline product or validated low-dose compounded preparation is far more practical.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • This whole-only 30 mg tablet cannot accurately deliver the approximately 1.88-2 mg oral dose studied in cats. Do not estimate one-sixteenth fragments or dispense loose hand-divided powder; use an authorised feline product or a pharmacy-validated low-dose preparation.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA feline mirtazapine2026
  5. Cat CKD mirtazapine RCT2013
  6. Cat mirtazapine PK PD2011
  7. Cat CKD mirtazapine PK2011
  8. Cat mirtazapine toxicosis2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Mirtazapine30 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Normon · Spain
Registration
Georgia Yes, human
In force until 11 Sep 2030
Human (Ministry of Health, RAMA)
In the register: მირტაზაპინი ნორმონი 30 მგ, აბი
№ რ-043965
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Mirtel 30 mg, Tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause
6.1/10
Situational / acceptable
vetman assessment

Mirtel

30 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-035312 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine has current evidence as a short-term second-line appetite stimulant in selected dogs, but this whole-only 30 mg human tablet is poorly scaled to many patients. Diagnose and treat the cause of hyporexia, use a validated patient-specific dose, review serotonergic combinations and escalate to assisted nutrition when intake remains inadequate.

Regulatory and scientific credibility6.0/10

The exact human 30 mg tablet has sourced current Georgian and EU/EEA registration and a transparent immediate-release identity, but no veterinary authorisation. Oral mirtazapine has current species evidence and professional-guideline support; those data do not validate this whole-only 30 mg presentation as a directly deliverable veterinary dose.

Clinical efficacy6.5/10

A 2025 study combined 107 retrospective clinical cases with a 25-dog placebo-controlled crossover trial: mirtazapine improved voluntary food acceptance on day 1 and was associated with less weight loss, but the prospective advantage was not maintained on day 2. This supports a useful short-term second-line role, not replacement of diagnosis, anti-nausea treatment or assisted enteral nutrition.

Safety and tolerability6.0/10

The current placebo-controlled study reported no short-term adverse effects, but canine safety numbers remain modest. Sedation or excitation, gastrointestinal signs, cardiovascular change and serotonin toxicity are plausible; human labelling and class pharmacology require review of serotonergic drugs, monoamine-oxidase inhibitors, organ disease and repeated exposure.

Clinical practicality5.5/10

A 30 mg whole-only tablet can match some very large dogs but is poorly scaled to many canine doses. Crushing may permit pharmacy compounding, but informal powder division or guessed fragments do not establish content uniformity; use a validated patient-specific preparation rather than improvised fractions.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • The 30 mg tablet is whole-only in the catalogue and is too large for many canine regimens. Do not assume that crushing makes home division accurate; use a pharmacy-validated patient-specific preparation when the prescribed dose is not a whole tablet.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA mirtazapine alternatives2023
  5. Dog appetite mirtazapine2025
  6. Dog mirtazapine PK2012
  7. AAHA nutrition guideline2021
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause
5.9/10
Weak evidence support
vetman assessment

Mirtel

30 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-035312 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine can improve appetite and weight and reduce vomiting in selected cats, especially those with stable CKD, but this whole-only 30 mg tablet is an unsafe practical match to the approximately 1.88-2 mg studied dose. Prefer an authorised feline formulation or an accurately prepared low-dose product and adjust monitoring for renal or hepatic disease.

Regulatory and scientific credibility6.0/10

The exact human 30 mg tablet has sourced current Georgian and EU/EEA registration and a transparent immediate-release identity, but no veterinary authorisation. Oral mirtazapine has current species evidence and professional-guideline support; those data do not validate this whole-only 30 mg presentation as a directly deliverable veterinary dose.

Clinical efficacy7.5/10

A masked placebo-controlled crossover trial in 11 cats with stable CKD found improved appetite and activity, reduced vomiting and median weight gain of 0.18 kg over three weeks; healthy-cat pharmacodynamic work also showed increased intake. Samples are small and do not establish equal benefit in every cause of feline hyporexia, but oral efficacy is clinically credible.

Safety and tolerability6.5/10

Feline oral studies define common behavioural and gastrointestinal effects and show slower clearance in renal and especially hepatic disease. An 84-case toxicosis series found vocalisation, agitation, vomiting, ataxia, tremor, tachypnoea and tachycardia, commonly after 15 mg accidental ingestion; an accurately measured low dose is therefore central to safety.

Clinical practicality2.0/10

The studied oral feline dose is about 1.88-2 mg, roughly one sixteenth of this 30 mg whole-only tablet. That dose cannot be delivered accurately by ordinary splitting, and accidental administration of 15-30 mg is a documented toxicosis pattern. A licensed feline product or validated low-dose compounded preparation is far more practical.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • This whole-only 30 mg tablet cannot accurately deliver the approximately 1.88-2 mg oral dose studied in cats. Do not estimate one-sixteenth fragments or dispense loose hand-divided powder; use an authorised feline product or a pharmacy-validated low-dose preparation.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA feline mirtazapine2026
  5. Cat CKD mirtazapine RCT2013
  6. Cat mirtazapine PK PD2011
  7. Cat CKD mirtazapine PK2011
  8. Cat mirtazapine toxicosis2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Mirtazapine30 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
G.L. Pharma · Austria
Registration
Georgia Yes, human
In force until 24 May 2027
Human (Ministry of Health, RAMA)
In the register: მირტელი 30 მგ, აბი
№ რ-035312
Verified on: 16 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Mirtoza 30 mg, Tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause
5.9/10
Weak evidence support
vetman assessment

Mirtoza

30 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Off-label short-term oral mirtazapine as a second-line appetite stimulant in dogs with clinically important hyporexia after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-041710 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine has current evidence as a short-term second-line appetite stimulant in selected dogs, but this whole-only 30 mg human tablet is poorly scaled to many patients. Diagnose and treat the cause of hyporexia, use a validated patient-specific dose, review serotonergic combinations and escalate to assisted nutrition when intake remains inadequate.

Regulatory and scientific credibility5.5/10

The exact human 30 mg tablet is currently registered in Georgia, but no exact EU/EEA, GB or US registration and no veterinary authorisation were found in the checked registers. Oral species evidence supports mirtazapine as an ingredient, not the dose accuracy or veterinary suitability of this exact whole-only presentation.

Clinical efficacy6.5/10

A 2025 study combined 107 retrospective clinical cases with a 25-dog placebo-controlled crossover trial: mirtazapine improved voluntary food acceptance on day 1 and was associated with less weight loss, but the prospective advantage was not maintained on day 2. This supports a useful short-term second-line role, not replacement of diagnosis, anti-nausea treatment or assisted enteral nutrition.

Safety and tolerability6.0/10

The current placebo-controlled study reported no short-term adverse effects, but canine safety numbers remain modest. Sedation or excitation, gastrointestinal signs, cardiovascular change and serotonin toxicity are plausible; human labelling and class pharmacology require review of serotonergic drugs, monoamine-oxidase inhibitors, organ disease and repeated exposure.

Clinical practicality5.5/10

A 30 mg whole-only tablet can match some very large dogs but is poorly scaled to many canine doses. Crushing may permit pharmacy compounding, but informal powder division or guessed fragments do not establish content uniformity; use a validated patient-specific preparation rather than improvised fractions.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • The 30 mg tablet is whole-only in the catalogue and is too large for many canine regimens. Do not assume that crushing makes home division accurate; use a pharmacy-validated patient-specific preparation when the prescribed dose is not a whole tablet.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA mirtazapine alternatives2023
  5. Dog appetite mirtazapine2025
  6. Dog mirtazapine PK2012
  7. AAHA nutrition guideline2021
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause
5.8/10
Weak evidence support
vetman assessment

Mirtoza

30 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Off-label short-term oral mirtazapine for appetite stimulation and selected nausea or vomiting associated with clinically important hyporexia in cats after diagnosis and treatment of the underlying cause · oral
Care settingVeterinary-prescribed home or hospital use within a measured nutrition plan, with an accurately compounded or otherwise validated patient-specific dose and reassessment of intake and weight
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-041710 · Verified on 16 Oct 2026 Off-label use

Oral mirtazapine can improve appetite and weight and reduce vomiting in selected cats, especially those with stable CKD, but this whole-only 30 mg tablet is an unsafe practical match to the approximately 1.88-2 mg studied dose. Prefer an authorised feline formulation or an accurately prepared low-dose product and adjust monitoring for renal or hepatic disease.

Regulatory and scientific credibility5.5/10

The exact human 30 mg tablet is currently registered in Georgia, but no exact EU/EEA, GB or US registration and no veterinary authorisation were found in the checked registers. Oral species evidence supports mirtazapine as an ingredient, not the dose accuracy or veterinary suitability of this exact whole-only presentation.

Clinical efficacy7.5/10

A masked placebo-controlled crossover trial in 11 cats with stable CKD found improved appetite and activity, reduced vomiting and median weight gain of 0.18 kg over three weeks; healthy-cat pharmacodynamic work also showed increased intake. Samples are small and do not establish equal benefit in every cause of feline hyporexia, but oral efficacy is clinically credible.

Safety and tolerability6.5/10

Feline oral studies define common behavioural and gastrointestinal effects and show slower clearance in renal and especially hepatic disease. An 84-case toxicosis series found vocalisation, agitation, vomiting, ataxia, tremor, tachypnoea and tachycardia, commonly after 15 mg accidental ingestion; an accurately measured low dose is therefore central to safety.

Clinical practicality2.0/10

The studied oral feline dose is about 1.88-2 mg, roughly one sixteenth of this 30 mg whole-only tablet. That dose cannot be delivered accurately by ordinary splitting, and accidental administration of 15-30 mg is a documented toxicosis pattern. A licensed feline product or validated low-dose compounded preparation is far more practical.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • No assessed 30 mg tablet is authorised for dogs or cats. Veterinary use is off-label; the human label does not provide a veterinary dose, safety margin or treatment duration.
  • This whole-only 30 mg tablet cannot accurately deliver the approximately 1.88-2 mg oral dose studied in cats. Do not estimate one-sixteenth fragments or dispense loose hand-divided powder; use an authorised feline product or a pharmacy-validated low-dose preparation.
  • Do not combine with a monoamine-oxidase inhibitor or use within its required washout period. Explicitly review SSRIs, SNRIs, tricyclics, tramadol, trazodone, linezolid, methylene blue and other serotonergic drugs; stop and assess urgently for agitation, tremor, hyperthermia, tachycardia, hypertension, diarrhoea or seizures.
  • Record baseline body weight, body- and muscle-condition scores and actual caloric intake. Reassess appetite, vomiting or nausea, weight, hydration and behaviour; monitor for sedation or hyperactivity, vocalisation, agitation, vomiting, salivation, ataxia, tremor, tachycardia or other toxicity.
  • Renal disease can increase mirtazapine exposure in cats and hepatic disease can markedly prolong half-life. Use a conservative patient-specific interval and closer monitoring in renal or hepatic dysfunction, geriatric or debilitated patients; do not copy a healthy-patient schedule.
  • Safety is insufficiently defined in pregnancy, lactation and very young animals. Avoid routine use unless the expected benefit clearly outweighs uncertainty and a more established alternative is unsuitable.
  • An appetite stimulant does not diagnose or correct pain, nausea, dental disease, gastrointestinal obstruction, systemic disease, food aversion or inadequate nutrition. Treat the cause and quantify intake; if voluntary intake remains inadequate, do not delay appropriate assisted enteral nutrition.
Assessment sources
  1. Georgia human register2026
  2. FDA human mirtazapine label2026
  3. AAHA oncology supportive care2026
  4. FDA feline mirtazapine2026
  5. Cat CKD mirtazapine RCT2013
  6. Cat mirtazapine PK PD2011
  7. Cat CKD mirtazapine PK2011
  8. Cat mirtazapine toxicosis2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Mirtazapine30 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Whan In Pharmaceutical · South Korea
Registration
Georgia Yes, human
In force until 26 Jul 2029
Human (Ministry of Health, RAMA)
In the register: მირტოზა 30 მგ, აბი
№ რ-041710
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗